ANDA 206177, held by Dfb Oncology Ltd. Docetaxel.
As of Nov 15, 2026, ANDA 206177 (Docetaxel), held by Dfb Oncology Ltd, was first approved by FDA on Jan 20, 2017, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 20, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
